- Home
- KZR vs MURA Comparison
KZR vs MURA Comparison
Compare KZR & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KZR
- MURA
- Stock Information
- Founded
- KZR 2015
- MURA 2013
- Country
- KZR United States
- MURA Ireland
- Employees
- KZR N/A
- MURA N/A
- Industry
- KZR Biotechnology: Pharmaceutical Preparations
- MURA
- Sector
- KZR Health Care
- MURA
- Exchange
- KZR Nasdaq
- MURA Nasdaq
- Market Cap
- KZR 29.7M
- MURA 30.7M
- IPO Year
- KZR 2018
- MURA N/A
- Fundamental
- Price
- KZR $4.01
- MURA $1.59
- Analyst Decision
- KZR Hold
- MURA Strong Buy
- Analyst Count
- KZR 2
- MURA 3
- Target Price
- KZR $9.00
- MURA $12.00
- AVG Volume (30 Days)
- KZR 81.6K
- MURA 206.3K
- Earning Date
- KZR 08-19-2025
- MURA 08-04-2025
- Dividend Yield
- KZR N/A
- MURA N/A
- EPS Growth
- KZR N/A
- MURA N/A
- EPS
- KZR N/A
- MURA N/A
- Revenue
- KZR N/A
- MURA N/A
- Revenue This Year
- KZR N/A
- MURA N/A
- Revenue Next Year
- KZR N/A
- MURA N/A
- P/E Ratio
- KZR N/A
- MURA N/A
- Revenue Growth
- KZR N/A
- MURA N/A
- 52 Week Low
- KZR $3.62
- MURA $0.95
- 52 Week High
- KZR $9.18
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- KZR 38.90
- MURA 15.71
- Support Level
- KZR $3.98
- MURA $1.53
- Resistance Level
- KZR $4.23
- MURA $2.40
- Average True Range (ATR)
- KZR 0.19
- MURA 0.15
- MACD
- KZR -0.04
- MURA -0.09
- Stochastic Oscillator
- KZR 9.56
- MURA 6.04
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.